RonaldEugeneGressMD

Oncology • Bethesda, MD

Chief, Experimental Transplantation and Immunology Branch, CCR, NCI, NIH

Join to view full profile

Dr. Gress is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gress' full profile

Already have an account?

Office
10 Crc3 3330
Nih
Bethesda, MD 20892
Phone+1 301-496-1791

Education & Training

Baylor College of MedicineClass of 1975

Certifications & Licensure

MD State Medical License 1978 - 2024
TX State Medical License 1975 - 1999
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1991
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer Start of enrollment: 1996 Jul 12
Completed
Phase 1
Genetic Analysis of Brain Tumors Start of enrollment: 2002 Mar 01
Terminated
Interleukin-7 in Treating Patients With Refractory Solid Tumors Start of enrollment: 2003 Apr 01
Completed
Phase 1
Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies Start of enrollment: 2003 Mar 06
Completed
Montelukast to Treat Bronchiolitis Obliterans Start of enrollment: 2008 Jun 17
Completed
Phase 2
Autologous and Related Allogeneic Hematopoietic Stem Cell Transplant Data Submission to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP) Start of enrollment: 2008 Dec 01
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2010 Jan 19
Terminated
Phase 2
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Mar 30
Terminated
Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Start of enrollment: 2011 Apr 19
Completed
Phase 2
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy Start of enrollment: 2011 Apr 01
Terminated
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Providing Access to Cord Blood Units for Transplants Start of enrollment: 2011 Oct 27
Withdrawn
Phase 2
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma Start of enrollment: 2012 Jul 01
Terminated
Phase 1, Phase 2
Vaccine Response With NT-I7 Start of enrollment: 2023 May 30
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

2 citations
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention.
Noa G Holtzman, Lauren M Curtis, Rachel B Salit, Brian C Shaffer, Filip Pirsl
Blood Advances. 2024-08-27
2 citations
Microbial ligand-independent regulation of lymphopoiesis by NOD1.
Chiaki Iwamura, Hidetaka Ohnuki, Francis A Flomerfelt, Lixin Zheng, Alexie Carletti
Nature Immunology. 2023-12-01
1 citations
In vivo deuterium magnetic resonance imaging of xenografted tumors following systemic administration of deuterated water.
Jeffrey R Brender, Julian C Assmann, Don E Farthing, Keita Saito, Shun Kishimoto
Scientific Reports. 2023-09-07

Journal Articles

Impact of the 2014 NIH Chronic Graft-Versus-Host Disease Scoring Criteria Modifications Assessed in a Large Cohort of Severely Affected Patients
Lauren M Curtis, Galen O Joe, Jacqueline W Mays, Ann Berger, Pamela Stratton, Ronald E Gress, Sandra A Mitchell, Steven Z Pavletic, Kristin Baird, Nature

Abstracts/Posters

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions ...
Ronald E. Gress, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Grant Support

Etib Clinical TrialsNational Cancer Institute2011
Etib Clinical Research CoreNational Cancer Institute2011
Transplant ModelsNational Cancer Institute2010–2011
Immune ReconstitutionNational Cancer Institute2010–2011
Clinical TrialsNational Cancer Institute2010
Branch Clinical Research CoreNational Cancer Institute2010
Transplant ModelsDivision Of Basic Sciences - Nci2009
Immune ReconstitutionDivision Of Basic Sciences - Nci2009
Clinical TrialsDivision Of Basic Sciences - Nci2009
Branch Clinical Research CoreDivision Of Basic Sciences - Nci2009
Transplant ModelsNational Cancer Institute2008
Clinical TrialsNational Cancer Institute2008
Branch Clinical Research CoreNational Cancer Institute2008
Immune ReconstitutionNational Cancer Institute2007–2008
Immune ReconstitutionDivision Of Basic Sciences - Nci2003–2006
Hematopoietic Stem Cell Gene Therapy For LADDivision Of Clinical Sciences - Nci2001